NMOSD
Clinical trials for NMOSD explained in plain language.
Never miss a new study
Get alerted when new NMOSD trials appear
Sign up with your email to follow new studies for NMOSD, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with rare nerve disease: satralizumab trial begins
Disease control Recruiting nowThis study tests a drug called satralizumab in children aged 2 to 11 who have a rare autoimmune disease called NMOSD. The main goal is to see how the drug moves through the body and if it can safely reduce relapses. Only 8 children will take part, and the results will help doctor…
Matched conditions: NMOSD
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Immune reset: CAR-T therapy targets lupus, MS, and more
Disease control Recruiting nowThis early-phase study tests a new treatment called RD06-05, which uses a patient's own immune cells modified to target and reset the immune system in autoimmune diseases like lupus, multiple sclerosis, and vasculitis. The goal is to check safety and how well the body tolerates i…
Matched conditions: NMOSD
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Can pregnancy and neurological disease coexist safely? a new registry seeks answers
Knowledge-focused Recruiting nowThis study is a pregnancy registry that gathers information from women with chronic neurological conditions like multiple sclerosis, NMOSD, and myasthenia gravis who are planning pregnancy, currently pregnant, or within one year postpartum. Participants can contribute blood, brea…
Matched conditions: NMOSD
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
New registry to monitor Real-World effects of NMOSD treatments
Knowledge-focused Recruiting nowThis study is a long-term registry for adults with AQP4+ neuromyelitis optica spectrum disorder (NMOSD) who are already taking Alexion C5 inhibitor drugs like eculizumab or ravulizumab. It will collect information on relapses, safety, and quality of life over many years to unders…
Matched conditions: NMOSD
Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC